Featuring perspectives from Dr Seth Wander, including the following topics:
- Case: A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ metastatic breast cancer (mBC), Recurrence Score® (RS) = 35 (0:00)
- Mechanisms of resistance to antiestrogen therapy in HR-positive mBC (2:33)
- Optimal approaches to biomarker assessment (15:37)
- Case (continued): A woman in her mid-50s with ER-positive, PR-negative, HER2 IHC 1+ mBC, RS = 35 (18:27)
- Case: A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (20:22)
- EMERALD — Phase III data guiding the use of elacestrant (21:39)
- Emerging oral selective estrogen receptor degraders — camizestrant and imlunestrant (29:32)
- Case (continued): A woman in her early 60s with de novo HR-positive, HER2-negative mBC with an ESR1 mutation after disease progression on first-line ribociclib/letrozole (45:44)
- Case: A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (47:22)
- CAPItello-291 — Phase III data guiding the use of capivasertib (48:52)
- Case (continued): A woman in her early 60s with HR-positive, HER2-negative mBC and a PIK3CA mutation who develops a new ESR1 mutation after disease progression on CDK4/6i and aromatase inhibitor (52:41)
- Additional promising antiestrogens — vepdegestrant and lasofoxifene (58:41)
